We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Source Bio. | SBS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 17.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.50 | 17.50 |
| Top Posts |
|---|
Posted at 16/9/2020 20:57 by p1nkfish SBS due to see a public offering in Sept 2020 according to NAS results today. |
Posted at 05/10/2016 18:53 by peterz Money paid. Good bye Sbs. Will be interested to see if money is now made by those that took the other option! Good luck. |
Posted at 09/9/2016 01:15 by buywell3 SBS are still listed and their shares are still trading on the LSESomebody seems to want them at over 18p Getting them though seems to be getting harder due to lack of sellers Cyprotex ( CRX) doing very well now Profits this year could now top 3m GBP Better than even SBS profits would have been ......... how I wish |
Posted at 01/9/2016 17:34 by p1nkfish Christopher Mills/Harwood doing similar in JNY now. Held them too and sold out. JNY being placed in a private vehicle, like SBS. |
Posted at 22/8/2016 07:28 by peterz Thanks bm. I am very unsure what to do. After holding for many years at a loss and selling would simply crystallise the significant loss, but would give me something back. On the other hand if I accept the alternative offer of unlisted securities what does anyone know of the potential??I guess its to do with trust really, I believed in SBS management and expected them to take the company to great things for long-term shareholders like me rather than taking the cash and admittadley pleasing themselves and some newer shareholders. |
Posted at 20/8/2016 17:52 by bigman peterzthe answer to your question is yes, any losses can be offset against future gains. Of course any gains would be subject CGT as well. The only other possible advantage is perhaps the unlisted shares would be excluded from IHT (after a qualifying period. SBS shares being fully listed are not excluded from IHT, unlike many on AIM. Hope that helps |
Posted at 05/8/2016 10:14 by p1nkfish This is just a thought.If you can't beat them, join them. Look back and see a link to Chris Mills, Harwood etc and various stakes in EKF, CRX (they have a lot of updside there), SBS. The way I see it NAS is a reasonable way to benefit from Mills. It is at a high but has reasons to be so. TridentIII has a hold over crx and the trust has interests in others I like - hayt, jny plus others. TER is not the lowest but for good reason. This is not advice but worth research. It is a buy and forget for me. Mills bought about £1M worth around Jan at about 10% below price today. Keep an eye on it and one to consider certainly if there is a market sell off. A diverse collection of smaller north atlantic co's with growth potential is a decent place to look. Gov needs them to prosper for employment, some are good exporters, they tend to grow quicker than large caps and Mills is very capable. If you do invest it's not one to speculate with due to the spread. It is a buy and hold or don't bother imho. I rolled my SBS sales proceeds into NAS and do hold. Good luck with everything, in and out of the markets. |
Posted at 03/8/2016 04:23 by p1nkfish N+1 think the offer doesn't fully value SBS.The advice is not to take the unlisted securities but SBS directors are all electing to do so. Easiest way to keep an interest is via NASCIT. Capitalism at work. I have been lucky here but was intending to build a good sized stake over time. I sold out on the basis there was a risk the offer may not happen on the advice of the SBS board and lost about 0.35p or so. The take-out was probably a done deal and the confirmation delay may have been to get the Directors on board somehow. If N+1 and the Directors both came out against it would have been a problem. If I was a director I would have used that as negotiating material to increase the benefit to the Directors - sweeten the deal for us or we come out against too with N+1. Have to wonder what the SBS directors have lined up. Keep an eye on what happens with crx that has loan notes with Trident that is related to Harwood etc. Long story there but again capitalism at work. Good luck everyone. |
Posted at 11/9/2015 15:59 by buywell2 Hello Diamond1 are you a SBS holder now ?Shares Mags read some advfn BB's methinks buywell3 29 Jul'15 - 08:23 - 3127 of 3213 0 0 A few thoughts Source Bioscience had a presence in Biocity prior to this latest acquisition From the Source Bioscience March 2015 results : 'Operational highlights • Overnight Service™ for DNA sequencing launched from new laboratories in Los Angeles, BioCity Scotland and Tramore, Ireland Presumably SBS had its eye on Select Pharma very soon after moving into Biocity if not before. The acquisition of Vindon Healthcare was questioned by many. Many investors sold up as they did not see the sense in acquiring a business that manufactured cold storage rooms. Vindon was located in Rochdale, a new SBS production facility involving Inverclyde products has now been recently located nearby in the same Kingsway business park which allows for future product expansion The latest Select Pharma acquisition also requires cold storage provision , not surprisingly one would imagine that Vindon units(now SBS owned) will be used in the future and most likely Select Pharma were already leasing some. It does not take much out of the box thinking to expect SBS to replicate this model in the USA in a year or two. The integration and replication of Select Pharma services at existing Source Bioscience USA facilities will surely come at some point soon, which will then enable greater market penetration particularly within the states concerned and the neighbouring states. SBS has now made many acquisitions, this will be the sixth Vindon was acquired by obtaining institutional cash at 9.5p , which was circa 23% discount on the circa 12.5p share price that SBS was trading at the time. Select Pharma , which is a private unlisted company , has been acquired using institutional cash at raised at a share price of 14p which was the share price at the time of the announcement Why is this ? Private investors have all but sold out now Over 90% of shares rested in the hands of existing institutional investors and SBS management BEFORE this acquisition After the acquisition this figure will rise to over 95% In short , there are hardly any shares left for PI's to trade. The next acquisition which I expect will come within 18 months to two years , will be similar to this one with just one difference I expect the cash raised next time will be at a premium to the SP why ? SBS turnover and profits for this year are already in the bag as there will be a whole years trading of Vindon products included PLUS there will be some numbers to add from Select Pharma , I now expect over £31.5m turnover ( just over a 20% 2014 rise )and this time over £3m profit, I don't expect too much in the way of charges/costs for the Select Pharma acquisition. Also has anyone noticed that the number of distributors selling SBS Life Sciences products and services has increased to 18 from a recent 13 some 6 months ago ? So a 2014 disappointing flat Life Sciences number should start heading north once more, plus Atlanta and the USA should start contributing. 2016 turnover and profits look set rise as there will be a whole year of Select Pharma turnover and profits to be added together with increased cross selling opportunities gained by SBS access to Select Pharma clients and vice versa plus there are no shares left so any new institution wanting a meaningful stake will have to pay for it. SBS management, though I give them a hard time of it sometimes, are proving to be able to deliver the goods. Their acquisition choices are coming good, have been bought at decent prices , the way that they are gelling together and each new one is helping the rest shows the plan is working. Controlled growth by acquisition is the name of the game SBS Market Cap is now over £50m , this might attract some new Institutions that have minimum market cap limits set for investment purposes. Within 4 years I expect to see Turnover of £50m which will help to do the same In short , SBS is starting to look like it might be another ABC dyor |
Posted at 29/7/2015 08:23 by buywell3 A few thoughtsSource Bioscience had a presence in Biocity prior to this latest acquisition From the Source Bioscience March 2015 results : 'Operational highlights • Overnight Service™ for DNA sequencing launched from new laboratories in Los Angeles, BioCity Scotland and Tramore, Ireland Presumably SBS had its eye on Select Pharma very soon after moving into Biocity if not before. The acquisition of Vindon Healthcare was questioned by many. Many investors sold up as they did not see the sense in acquiring a business that manufactured cold storage rooms. Vindon was located in Rochdale, a new SBS production facility involving Inverclyde products has now been recently located nearby in the same Kingsway business park which allows for future product expansion The latest Select Pharma acquisition also requires cold storage provision , not surprisingly one would imagine that Vindon units(now SBS owned) will be used in the future and most likely Select Pharma were already leasing some. It does not take much out of the box thinking to expect SBS to replicate this model in the USA in a year or two. The integration and replication of Select Pharma services at existing Source Bioscience USA facilities will surely come at some point soon, which will then enable greater market penetration particularly within the states concerned and the neighbouring states. SBS has now made many acquisitions, this will be the sixth Vindon was acquired by obtaining institutional cash at 9.5p , which was circa 23% discount on the circa 12.5p share price that SBS was trading at the time. Select Pharma , which is a private unlisted company , has been acquired using institutional cash at raised at a share price of 14p which was the share price at the time of the announcement Why is this ? Private investors have all but sold out now Over 90% of shares rested in the hands of existing institutional investors and SBS management BEFORE this acquisition After the acquisition this figure will rise to over 95% In short , there are hardly any shares left for PI's to trade. The next acquisition which I expect will come within 18 months to two years , will be similar to this one with just one difference I expect the cash raised next time will be at a premium to the SP why ? SBS turnover and profits for this year are already in the bag as there will be a whole years trading of Vindon products included PLUS there will be some numbers to add from Select Pharma , I now expect over £31.5m turnover ( just over a 20% 2014 rise )and this time over £3m profit, I don't expect too much in the way of charges/costs for the Select Pharma acquisition. Also has anyone noticed that the number of distributors selling SBS Life Sciences products and services has increased to 18 from a recent 13 some 6 months ago ? So a 2014 disappointing flat Life Sciences number should start heading north once more, plus Atlanta and the USA should start contributing. 2016 turnover and profits look set rise as there will be a whole year of Select Pharma turnover and profits to be added together with increased cross selling opportunities gained by SBS access to Select Pharma clients and vice versa plus there are no shares left so any new institution wanting a meaningful stake will have to pay for it. SBS management, though I give them a hard time of it sometimes, are proving to be able to deliver the goods. Their acquisition choices are coming good, have been bought at decent prices , the way that they are gelling together and each new one is helping the rest shows the plan is working. Controlled growth by acquisition is the name of the game SBS Market Cap is now over £50m , this might attract some new Institutions that have minimum market cap limits set for investment purposes. Within 4 years I expect to see Turnover of £50m which will help to do the same In short , SBS is starting to look like it might be another ABC dyor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
